EML3

Across TCGA pan-cancer cohorts, EML3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EML3 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher EML3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EML3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

LSCC, HNSC, and PDAC are the cancer types where EML3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	II,III,IV	0.540	1.000	.002	46	view →
HNSC	DFS	Tertile	II,III,IV	0.594	0.854	.017	14	view →
PDAC	DFS	Quartile	II,III,IV	0.555	0.289	.021	10	view →
CCRCC	OS	Tertile	II,III,IV	0.704	0.995	.013	8	view →
UCEC	DFS	Median	II,III,IV	0.535	0.880	.040	4	view →
LUAD	DFS	Tertile	All	0.746	0.437	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EML3–LSCC (OS)

Open the LSCC breakdown →